


FDA Responds to New Drug Application for Baricitinib
Highlights from the Second Annual ACR Division Directors’ Conference

Draft Criteria for ANCA-Associated Vasculitis Released

Update on Legislation, Notification Rules Concerning the Substitution of Interchangeable Biologic Drugs

Rheumatology Drug Updates: Infliximab Biosimilar Cross Reacts to Infliximab Antibodies

Resarch Into IgG4-Related Diseases Expands Knowledge Base, Leads to Effective Treatments
